Organization · Venture Capital
EMV Capital
EMV Capital is a London-based venture capital investment group that specializes in early-stage deep tech and life sciences companies. They employ a capital-efficient investment strategy and have a diverse portfolio across various sectors.
Overview
What EMV Capital does
What EMV Capital is
EMV Capital is a London-based venture capital investment group that specializes in early-stage deep tech and life sciences companies. They employ a capital-efficient investment strategy and have a diverse portfolio across various sectors.
How it participates in the startup ecosystem
The current public profile supports funder and publisher capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2018
- Approximate age
- About 8 years
- Structured capabilities
- Funder · Publisher
- Last reviewed
- April 9, 2026
Official channels
Find EMV Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
EMV Capital as a funder
Investment thesis
EMV Capital focuses on investing in early-stage companies within deep tech and life sciences, leveraging a capital-efficient model to generate superior returns through strategic investments and proactive management.
Focus narrative
EMV Capital invests in early-stage companies within the deep tech and life sciences sectors. Their investment strategy includes capital-efficient investments through their PLC balance sheet, fund management of the Evergreen EIS and Martlet Capital Funds, and syndicated investments leveraging a network of third-party investors. The organization emphasizes proactive management and value creation services to support portfolio companies from their early stages through to successful exits.
Value beyond capital
EMV Capital provides proactive management and value creation services to its portfolio companies, supporting them from early stages through to successful exits. Their strategic investments and extensive network of third-party investors enhance the growth potential of their portfolio.
Focus and fit
- Stages
- Seed · Pre-seed · Series A
- Regions
- EuropeUnited Kingdom
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 70
- Recorded notable exits
- Abcam, Cambridge CMOS Sensors, Arachnys, and Audio Analytic
Portfolio context
EMV Capital manages a diverse portfolio of over 70 companies, including notable firms such as PDS Biotechnology, which focuses on harnessing the immune system to fight cancer; Glycotest, a diagnostics company developing blood tests for liver diseases; and Sofant Technologies, specializing in advanced antenna technology. Other significant companies include EpiBone, which advances skeletal reconstruction through 3D design and living cells, and Wanda Health, focusing on healthcare technology solutions.
Capability profile
EMV Capital as a publisher
Editorial focus
EMV Capital focuses on investing in early-stage companies within the deep tech and life sciences sectors. Their investment strategy includes capital-efficient investments through their PLC balance sheet, fund management of the Evergreen EIS and Martlet Capital Funds, and syndicated investments leveraging a network of third-party investors. The organization emphasizes proactive management and value creation services to support portfolio companies from their early stages through to successful exits.
Audience value
EMV Capital aims to generate superior returns for investors through strategic investments in high-growth sectors and technologies, leveraging a capital-efficient model and a strong portfolio of innovative companies.
Availability
- Guest pitch state
- Not currently accepting
Audience and focus
- Audience
- Investors
- Regions
- EuropeUnited Kingdom
Flagship work and coverage
Flagship properties
EMV Capital manages a diverse portfolio of over 70 companies, including notable firms such as PDS Biotechnology, Glycotest, Sofant Technologies, EpiBone, Vortex, and Wanda Health.
Notable coverage
The CEO of EMV Capital has been featured on Proactive Investors discussing the organization's milestone of over £100M AUM and its strategic focus on deep tech and life sciences.
Common questions
What to know about EMV Capital
Upseed classifies EMV Capital under the Venture Capital organization type. Its current public profile includes funder and publisher capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 9, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.